These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 24375440

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 3. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A.
    Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
    Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, Kanai Y, Ichikawa T.
    J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 14. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
    Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, Murphy C, Morgan R, Morash C, Parulekar W, Parmar M, Savage C, Stansfeld J, Sydes M, RADICALS Trial Management Group.
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI, Kakouratos C, Kalamida D, Mitrakas A, Pouliliou S, Xanthopoulou E, Papadopoulou E, Fasoulaki V, Giatromanolaki A.
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [Abstract] [Full Text] [Related]

  • 17. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL, Festuccia C, Galatioto GP, Muzi P, Angelucci A, Ronchi P, Costa AM, Bologna M, Vicentini C.
    Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R, Han J, Liang X, Sun S, Jiang Y, Xia B, Niu M, Li D, Zhang J, Wang S, Wei W, Liu Q, Zheng W, Zhang G, Song Y, Panga D.
    Cell Physiol Biochem; 2017 Oct; 43(6):2212-2225. PubMed ID: 29069648
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.